Amneal Pharmaceuticals
AMRX
144 hedge funds and large institutions have $135M invested in Amneal Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 46 increasing their positions, 48 reducing their positions, and 22 closing their positions.
128% more call options, than puts
Call options by funds: $66K | Put options by funds: $29K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 48
2.62% less ownership
Funds ownership: 66.5% → 63.88% (-2.6%)
8% less funds holding
Funds holding: 156 → 144 (-12)
33% less capital invested
Capital invested by funds: $202M → $135M (-$67.5M)
55% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
+$8.67M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.74M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$996K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$688K |
| 5 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$648K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$7.64M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$5.26M |
| 3 |
Millennium Management
New York
|
-$3.82M |
| 4 |
O
OrbiMed
New York
|
-$3.15M |
| 5 |
IA
IFP Advisors
Tampa,
Florida
|
-$1.97M |
AMRX Hedge Fund Activity: Q1 2023 in Review
144 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q1 2023, worth a combined $135M — down 33% from $202M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of AMRX and 10 opened new positions — a net loss of 12 holders — while 48 trimmed existing stakes and 46 added.
The largest buyer was Eversept Partners, adding an estimated $8.67M. The largest seller was Morgan Stanley, cutting an estimated $7.64M.
- 144 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q1 2023, down from 156 in Q4 2022.
- Funds reported $135M of Amneal Pharmaceuticals stock for Q1 2023, down 33% quarter-over-quarter.
- 10 funds opened new Amneal Pharmaceuticals positions in Q1 2023 and 22 closed out, a net change of -12 holders.
- The largest Amneal Pharmaceuticals buyer in Q1 2023 was Eversept Partners, an estimated $8.67M added.
- The largest Amneal Pharmaceuticals seller in Q1 2023 was Morgan Stanley, an estimated $7.64M sold.
Based on aggregated 13F filings for Q1 2023.